Massachusetts is currently home to 3215 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
NCT06456593
Recruiting
This study has 3 treatment phases, a 12-Week Induction Phase, a 40-Week Maintenance Phase, and a 48-Week Extension Phase. The objective is to evaluate the efficacy and safety of obefazimod compared to placebo as induction and maintenance therapy in subjects with moderately to severely active CD after inadequate response (no response, loss of response, or intolerance) to conventional therapies and/or advanced therapies. The primary objective for the 48-Week Extension Phase is to evaluate the sa... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/19/2025
Locations: Lucida Clinical Trials, LLC, New Bedford, Massachusetts
Conditions: Moderately to Severely Active Crohn Disease
Register for Updates
RECOVER-ENERGIZE Platform Protocol
NCT06404047
Recruiting
This is a platform protocol designed to be flexible so that it is suitable for a range of interventions and settings within diverse health care systems and community settings with incorporation into clinical COVID-19 management programs and treatment plans if results achieve key study outcomes. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating interventions to address and improve exercise intolerance and post-exertional malaise (PEM) as ma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Tufts Medical Center, Boston, Massachusetts
Conditions: Long COVID, Long Covid19, Long Covid-19
Register for Updates
Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
NCT06333262
Recruiting
This study will evaluate fixed-duration therapy with pirtobrutinib and obinutuzumab given over 12 cycles (approximately 1 year) as first-line treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL or SLL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Register for Updates
A Study of Opportunistic Salpingectomy to Prevent Ovarian Cancer
NCT06312124
Recruiting
The purpose of this study is to find out how many participants are interested in a surgical preventive procedure after watching an educational video. Before and after watching the video, participants will complete questionnaires in the clinic.
Gender:
FEMALE
Ages:
45 years and above
Trial Updated:
05/19/2025
Locations: Dana Farber Cancer Institute (Data Collection Only), Boston, Massachusetts
Conditions: Surgery
Register for Updates
ZILRETTA in Subjects With Shoulder Osteoarthritis
NCT06269705
Recruiting
Primary Objective: To assess the efficacy of ZILRETTA on pain following an intra-articular (IA) injection in subjects with glenohumeral osteoarthritis (OA) relative to normal saline placebo Secondary Objective: * To assess the efficacy of ZILRETTA on pain following an IA injection in subjects with glenohumeral OA relative to triamcinolone acetonide injectable suspension, immediate release (TCA-IR) and normal saline placebo * To assess the safety of ZILRETTA in subjects with glenohumeral OA rel... Read More
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
05/19/2025
Locations: New England Baptist Hospital, Boston, Massachusetts
Conditions: Glenohumeral Osteoarthritis
Register for Updates
A Ph2 Study of Glofitamab Alone or With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
NCT06043674
Recruiting
This research is being done to evaluate Glofitamab by itself or in combination with Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab as possible treatments for Chronic Lymphocytic Leukemia (CLL) that has transformed into Richter's Transformation (RT). The names of the study drugs involved in this research study are: * Glofitamab (a T-cell bispecific humanized monoclonal antibody) * Obinutuzumab (a humanized glycoengineered type II anti-CD20 monoclonal antibody) * Polatuzumab vedotin (an ant... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Chronic Lymphocytic Leukemia, Richter's Transformation
Register for Updates
Cardiac RADIoablation Versus Repeat Catheter Ablation: a Pivotal Randomized Clinical Trial Evaluating Safety and Efficacy for Patients With High-risk Refractory Ventricular Tachycardia (RADIATE-VT)
NCT05765175
Recruiting
RADIATE-VT is a pivotal, multicenter, randomized trial comparing safety and efficacy between cardiac radioablation (CRA) using the Varian CRA System and repeat catheter ablation (CA), for patients with high-risk refractory ventricular tachycardia (VT) who have experienced VT recurrence after CA and are candidates for additional CA.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Brigham & Women's Hospital, Boston, Massachusetts
Conditions: Tachycardia, Ventricular
Register for Updates
Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma
NCT05739942
Recruiting
This study will investigate different doses of \[177Lu\]Lu-NeoB in combination with RT and TMZ in participants with newly diagnosed glioblastoma, with methylated or unmethylated promoter, to assess the safety and efficacy of \[177Lu\]Lu-NeoB in combination with the SoC and in recurrent glioblastoma as single agent, to identify the recommended dose and to also explore the safety of the PET imaging agent \[68Ga\]Ga-NeoB and characterize its uptake in the tumor area.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/19/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Newly Diagnosed and Recurrent Glioblastoma
Register for Updates
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
NCT05680922
Recruiting
This is a phase 1, first-in-human, open-label, multicenter, dose escalation and expansion study of DLL3-targeted chimeric antigen receptor T-cells in subjects with extensive stage small cell lung cancer or large cell neuroendocrine lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Small Cell Lung Cancer Extensive Stage, Large Cell Neuroendocrine Carcinoma of the Lung
Register for Updates
CARv3-TEAM-E T Cells in Glioblastoma
NCT05660369
Recruiting
The goal of this research study is to determine the best dose of CARv3-TEAM-E T Cells for treating participants with glioblastoma. The name of the treatment intervention used in this research study is: -CARv3-TEAM-E T Cells (or Autologous T lymphocytes).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Glioma
Register for Updates
TriPRIL CAR T Cells in Multiple Myeloma
NCT05020444
Recruiting
This research study involves the study of TriPRIL CAR T Cells for treating people with relapsed or refractory multiple myeloma and to understand the side effects when treated with TriPRIL CAR T Cells. This research study involves the study drugs:. * TriPRIL CAR T Cells * Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Multiple Myeloma, Multiple Myeloma in Relapse, Refractory Multiple Myeloma
Register for Updates
Resilience and Equity in Aging, Cancer, and Health (REACH)
NCT04674267
Recruiting
The purpose of this multi-phase research study is to understand how consultation of cancer care with a geriatrician can best improve outcomes for older adults with gastrointestinal malignancies.
Gender:
ALL
Ages:
70 years and above
Trial Updated:
05/19/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Gastric Cancer, Colon Cancer, Esophageal Cancer, Rectal Cancer, Pancreatic Cancer, Gastrointestinal Cancer
Register for Updates